KRYS - Krystal Biotech Inc. (KRYS) Q1 2024 Earnings Call Transcript

2024-05-06 11:44:08 ET

Krystal Biotech, Inc. (KRYS)

Q1 2024 Earnings Conference Call

May 06, 2024 8:30 AM ET

Company Participants

Stéphane Paquette - VP, Business Development

Krish Krishnan - Chairman and CEO

Suma Krishnan - President of R&D

Christine Wilson - Head of U.S. Sales and Marketing

Jennifer McDonough - SVP, Patient Access, Analytics and Operations

Kate Romano - Chief Accounting Officer

Conference Call Participants

Alec Stranahan - Bank of America

Tim Lugo - William Blair

Ritu Baral - TD Cowen

Benazir Ali - Stifel

Andrea Tan - Goldman Sachs

Gavin Clark-Gartner - Evercore ISI

Yigal Nochomovitz - Citigroup

Presentation

Operator

Thank you for standing by and welcome to Krystal Biotech's First Quarter 2024 Earnings Conference Call. At this time, all participants are on a listen-only mode. After the speakers' presentations, there will be a question-and-answer session. During the question-and-answer session, there will be a limit of two questions per participants. As a reminder, today's conference is being recorded.

I would now like to hand the conference over to your host, Stéphane Paquette, Vice President of Corporate Development. Please begin.

Stéphane Paquette

Good morning and thank you all for joining today's call. Earlier today, we released our financial results for the first quarter of 2024. The press release is available on our website at www.krystalbio.com. We also filed our earnings 8-K and 10-Q with the SEC earlier today. Joining me today will be Krish Krishnan, Chairman and Chief Executive Officer; Suma Krishnan, President of Research and Development; Jennifer McDonough, Senior Vice President of Patient Access, Analytics and Operations; Christine Wilson, Senior Vice President and Head of U.S. Sales and Marketing, and Kate Romano, Chief Accounting Officer.

This conference call will, and our responses to questions may, contain forward-looking statements. You are cautioned that not to rely on these forward-looking statements, which are based on current expectations using the information available as of the date of this call and are subject to certain risks and uncertainties, then they cause the company's actual results to differ materially from those projected. A description of these risks, uncertainties, and other factors can be found in our SEC filings.

With that, I will turn the call over to Krish.

Krish Krishnan

Thank you, Stefan, and thank you all for joining Krystal's conference call. I'm pleased to share that the momentum in 2023 continues with a strong start to 2024, driven by excellent execution across all parts of our business, commercial, clinical, and manufacturing. VYJUVEK is reaching more and more patients by the day and is rapidly changing the treatment paradigm for patients suffering from this debilitating disease, Dystrophic Epidermolysis Bullosa or DEB. Increasingly, DEB patients are able to benefit from the durable wound healing afforded by VYJUVEK through fundamental genetic correction and also the convenience of being administered at home as a topical [chap] (ph)....

For further details see: